Peringkat dalam Saham
#5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Harga Saham
$36.98
Terakhir disinkronkan: 2026-08-26
Kapitalisasi Pasar
$2.58B
Perubahan (1 hari)
-0.67%
Perubahan (1 tahun)
55.51%
Perdagangan Pharvaris N.V. (PHVS)
Harga PHVS dengan kapitalisasi pasar B
Kapitalisasi pasar dari Pharvaris N.V.(PHVS)
Kapitalisasi Pasar: $2.58B
Per August 2026, Pharvaris N.V. memiliki kapitalisasi pasar sebesar $2.58B. Ini menjadikan Pharvaris N.V. sebagai perusahaan 5577th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Pharvaris N.V. dari 2021 hingga 2026
PHVS dibandingkan dengan 5 teratas stocks paling populer
| Harga PHVS |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.088T
|
+196,787.13%
|
|
|
|
|
$4.629T
|
+179,033.69%
|
|
|
|
|
$4.118T
|
+159,240.09%
|
|
|
|
|
$3.687T
|
+142,566.18%
|
|
|
|
|
$2.800T
|
+108,238.93%
|
